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The replication of human immunodeficiency virus (HIV) in CD4+ T-cells is strongly dependent upon the state of activation of infected cells.
Infection of sub-optimally activated cells is believed to play a critical role in both the transmission of virus and the persistence of CD4+ T-cell
reservoirs. There is accumulating evidence that HIV can modulate signal-transduction pathways in a manner that may facilitate replication in such
cells. We previously demonstrated that HIV gp120 induces virus replication in resting CD4+ Tcells isolated fromHIV-infected individuals. Here, we
show that in resting CD4+ T-cells, gp120 activates NFATs and induces their translocation into the nucleus. The HIV LTR encodes NFAT recognition
sites, and NFATs may play a critical role in promoting viral replication in sub-optimally activated cells. These observations provide insight into a
potential mechanism by which HIV is able to establish infection in resting cells, which may have implications for both transmission of HIVand the
persistence of viral reservoirs.
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The human immunodeficiency virus (HIV) infects CD4+ T
cells and macrophages, eventually inducing the depletion of
CD4+ T cells, the defining feature of acquired immunodefi-
ciency syndrome (AIDS) (Haase, 1999). Although current
antiretroviral therapies (ART) can reduce plasma viral loads to
undetectable levels, latent viral reservoirs persist (Kulkosky and
Pomerantz, 2002). Resting or sub-optimally activated CD4+ T-
cells constitute one such reservoir (Chun et al., 1997). Low-
level viral replication within this reservoir slows the rate at0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.09.052
Abbreviations: FBS, fetal bovine serum; EMSA, electrophoretic mobility
shift assay; R5, CCR5; X4, CXCR4; PBMCs, peripheral blood mononuclear
cells; GPCRs, G-protein coupled receptors; Ca2+, calcium; Al, microliter;
NFAT, nuclear factor of activated T-cells; bp, base pairs; PBS, phosphate
buffered saline; TCR, T cell receptor.
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1 These two authors equally contributed.which the reservoir decays and reduces the possibility that ART
could clear virus from the host. Therefore, it is important to
understand the events that permit the propagation of infection in
these cells in the absence of frank activation.
We and others have shown that gp120 transduces signals
through CCR5 (Davis et al., 1997; Weissman et al., 1997).
Subsequently, we and others demonstrated that CC chemokine-
mediated signal transduction through CCR5 enhances viral
replication in CD4+ T-cells (Kinter et al., 1998) and macrophages
(Kelly et al., 1998). Moreover, we found that envelope-mediated
signal transduction promotes viral replication in the resting CD4+
T-cell reservoir. In this regard, exposure of CD4+/CD25-/CD69-/
HLADR-T-cells isolated from HIV-infected individuals to R5
gp120 induces viral replication (Kinter et al., 2003).
To better understand the molecular mechanisms whereby
gp120 promotes viral replication under these conditions, we
evaluated the response of unstimulated PBMCs to gp120
treatment using high-density DNA microarrays and observed
an increase in the expression of a number of genes conducive to6) 105 – 114
www.e
Fig. 1. EMSA of PBMCs treated with an R5 and X4 gp120. Freshly isolated
PBMCs were treated with either a mock protein preparation, an R5 gp120
(92UG037) or an X4 gp120 (NL4-3), and nuclear lysates were generated
Lysates were probed with a biotinylated oligonucleotide probe encoding the
human IL2 NFAT recognition sequence, electrophoresed, transferred to nylon
membrane and incubated with a streptavidin-chemiluminescent conjugate
Mock treated (lane 1), X4 gp120 treated (lane 3) and R5 gp120 (lane 5), along
with replicate samples probed in the presence of excess unlabeled probe
encoding the human IL2 NFAT recognition sequence (lanes 2, 4, 6) are shown
C. Cicala et al. / Virology 345 (2006) 105–114106viral replication (Cicala et al., 2002). Among these genes was the
transcription factor Nuclear Factor of Activated T-cells (NFAT).
In addition to demonstrating increased NFAT transcription, we
also observed increased expression of NFAT1 protein (Cicala et
al., 2002).
Proteins belonging to the NFAT family of transcription factors
(NFAT1, NFAT2, NFAT3, NFAT4, NFAT5) play a central role in
the regulation of gene transcription associated with immune
responses (Rao et al., 1997). Different NFATs exhibit tissue
specific distribution and function. NFAT1 and NFAT2 proteins are
expressed both in T cells and macrophages where they play a
pivotal role in the transcription of cytokine genes and other genes
critical for the immune response. Of note, the HIV long terminal
repeat (LTR) encodes NFAT recognition sites and both NFAT1
and NFAT2 induce replication of HIV in primary cells (Cron et
al., 2000; Kinoshita et al., 1998). NFAT proteins are activated by
stimulation of receptors that are linked to calcium (Ca2+)
mobilization and to heterotrimeric G protein coupled receptors
(Yellaturu et al., 2002). Highly phosphorylated inactive forms of
NFAT reside in the cytoplasm. NFATs are activated and
translocated to the nucleus as a consequence of dephosphoryla-
tion. The activation state of NFATs are regulated by several
factors including the calcium/calmodulin-regulated serine/threo-
nine phosphatase, calcineurin and multiple inducible and
constitutive kinases (Rao et al., 1997). In light of previous
observations demonstrating that NFATs can play a critical role in
the replication of HIV in resting cells (Cron et al., 2000; Kinoshita
et al., 1998; Williams et al., 2004), the purpose of the present
study is to further characterize the NFAT-associated response of
primary CD4+ T cells to gp120 mediated-signal transduction.
Previously, we demonstrated that CCR5-tropic (R5) envel-
opes induce Ca2+ mobilization in unstimulated CD4+ T-
lymphocytes (Weissman et al., 1997). In this report, we asked
whether R5 envelopes can induce the activation and transloca-
tion of NFAT proteins in unstimulated primary cells. We show
that R5 gp120 stimulation does activate NFAT in resting CD4+
primary T-cells. We further show that CXCR4-tropic (X4) tropic
gp120s also induce the activation and translocation of NFAT
proteins. We demonstrate that optimal gp120-mediated NFAT
activation occurs as a consequence of coordinate signaling
through CD4 and either CCR5 or CXCR4, underscoring the
unique dual-signaling potential of gp120. Finally, we show that
gp120-activated NFAT binds multiple NFAT recognition sites
encoded within the HIV LTR. Because replication of HIV is
responsive to NFAT, the capacity of HIV gp120 to activate
NFATs in resting cells represents a potential mechanism that may
facilitate viral replication in this T-cell subset, and highlights a
potential target for future development of antiretroviral therapies
(Pessler and Cron, 2004).
Results
HIV-1 gp120-mediated activation of NFAT in human PBMCs
HIV gains entry into cells through a fusogenic process that
takes place on the surface of the cell membrane. The gp120
subunit of the viral envelope first engages CD4, followed by asecond interaction with a seven transmembrane G protein-
coupled chemokine receptor, in most instances either CCR5 or
CXCR4. gp120 engagement results in Ca2+ mobilization
(Kornfeld et al., 1988; Weissman et al., 1997). Of note, NFAT
activation is mediated by the mobilization of Ca2+ stores (Rao
et al., 1997). In resting cells, phosphorylated NFAT proteins
reside in the cytoplasm. In their phosphorylated state, they
exhibit a low affinity for their recognition sequences. Stimuli
that elicit Ca2+ mobilization promote the rapid dephosphory-
lation of NFATs and their translocation to the nucleus, where
the dephosphorylated proteins exhibit increased affinity for
NFAT recognition sequences (Rao et al., 1997). To examine the
ability of HIV envelope to activate NFAT we employed an
EMSA of nuclear extracts. Freshly isolated PBMCs were
treated with HIV gp120 for 4 h after which nuclear extracts
were obtained. We carried out an EMSA in which a probe
encoding the NFAT recognition sequence encoded in the
human IL2 promoter region was employed. Because some
HIV gp120s, in addition to binding CD4, recognize CCR5
while others recognize CXCR4, we evaluated the response of
both R5- and X4-tropic gp120s. Relative to mock-treated cells,
we observed increased binding activity in nuclear lysates,
indicating increased nuclear localization in response to both R5
and X4 gp120 treatment (Fig. 1). This signal was eliminated by
inclusion of excess unlabeled competing probe. We conclude
that both R5 and X4 gp120s are capable of inducing the
activation and nuclear translocation of NFAT.
CD4 crosslinking, Mip-1b and SDF-1 treatment
HIV gp120 transduces signals through both CD4 and CCR5
or CXCR4 (Banda et al., 1992; Davis et al., 1997; Juszczak et
al., 1991; Kornfeld et al., 1988; Weissman et al., 1997). To.
.
.
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CXCR4 signaling in mediating NFAT nuclear translocation, we
stimulated purified PBMCs with an anti-CD4 monoclonal
antibody (mAb) to mimic gp120–CD4 engagement, and with
SDF-1 or Mip-1h alone to mimic CXCR4 or CCR5 engage-
ment, respectively. We also combined the CD4 mAb with SDF-1
or Mip-1h to recapitulate a near-simultaneous stimulus of both
receptors, similar to that triggered by R5 or X4 gp120s. As
described above, we employed an oligonucleotide encoding theFig. 2. EMSA of PBMCs treated with h-chemokines and an anti-CD4 mAb. Freshly
and/or a crosslinked anti-CD4 mAb (A, lanes 1, 3, 5, 7, 9 and 11). Nuclear lysates w
NFAT recognition sequence, electrophoresed, transferred to nylon membrane and in
probed in the presence of excess unlabeled probe encoding the human IL2 NFAT rec
derived from Mip-1h plus crosslinked anti-CD4 mAb and SDF-1 plus crosslinked an
2, 4, and 7). These lysates were also probed with a nonbinding derivative of the I
displayed in panel Awas carried out with an oct-1 control probe (C). Freshly isolated
(D, lane 3) of TAK779, or an X4 envelope in the absence (D, lane 4) or presenceNFAT distal binding site on the IL-2 promoter as a probe and
carried out an EMSA (Fig. 2). We observed minimal to no NFAT
activation when cells were treated with SDF-1 or Mip-1h alone.
Similarly, the CD4 mAb did not activate NFAT. In repeated
experiments utilizing SDF-1 or Mip-1h alone we infrequently
observed a low level of NFAT activation (data not shown). In
contrast, when both CD4 and the co-receptor, either CCR5 or
CXCR4, were stimulated by their respective ligands, we
observed a marked activation of NFAT. The level of activationisolated PBMCs were treated with a mock protein preparation, Mip-1h, SDF-1,
ere probed with a biotinylated oligonucleotide probe encoding the human IL2
cubated with a streptavidin-chemiluminescent conjugate. Replicate treatments
ognition sequence are also included (A, lanes 2, 4, 6, 8, 10 and 12). The lysates
ti-CD4 mAb were also assayed in the presence of an anti-NFAT mAb (B, lanes
L2 NFAT recognition sequence (B, lanes 5 and 8). An EMSA with all lysates
PBMCs were treated with an R5 envelope in the absence (D, lane 2) or presence
(D, lane 5) of AMD3100.
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engagement of CD4 and either CCR5 or CXCR4. To
demonstrate the specificity of these binding activities we
employed two controls: anti-NFAT mAbs as supershift controls
(Fig. 2B), and a nonbinding derivative of the NFAT recognition
sequence in the IL2 promoter (Fig. 2B). Supershifting with
mAbs . Supershifting the probe-transcription factor complex
with a specific antibody commonly results in three alternative
outcomes: the band can completely disappear, or it can be
completely supershifted to a slower migrating complex, or it can
be partially supershifted (Carey, 2000). In this case supershifting
with NFAT mAbs reduced the signal relative to that obtained
from lysates derived from cells treated with either SDF-1 or
MIP1-h in combination with CD4 crosslinking. With these same
lysates we also employed a nonbinding NFAT control probe,
which resulted in a marked reduction in the signal relative to that
obtained with the wild-type IL2 promoter NFAT oligonucleotide
(Fig. 2B). In contrast when these lysates were probed with an
oligonucleotide specific oct-1, a factor constitutively present in
the nucleus, similar signals were observed (Fig. 2C). These
results further support our conclusion that coordinate signaling
through CD4 and coreceptor induces NFAT activation. We did
note low-level residual binding to the control probe, however the
signal was significantly reduced relative to the signal obtained
with wild-type probe. In addition, we observed several fast-
migrating bands of low-intensity, the identities of which are
unknown. Finally, to demonstrate that gp120-mediated NFAT
activation is dependent upon coreceptor engagement (either
CCR5 or CXCR4) we employed TAK779 and AMD3100 (Baba
et al., 1999; Schols et al., 1997), specific inhibitors of CCR5 and
CXCR4 respectively (Fig. 2D). Both of these chemokine
receptor-specific inhibitors strongly inhibited gp120-mediated
NFAT activation, further demonstrating that CD4 engagement
alone does not activate NFAT.
HIV-1 gp120 induces NFAT binding to the HIV-LTR
enhancer–promoter
The HIV LTR encodes several regulatory elements recog-
nized by host cell transcription factors including NFnB and
NFAT (Pessler and Cron, 2004). As a consequence, viral
transcription and replication are linked to major host cell
signaling pathways and are regulated by the activation state of
an infected cell. There are multiple NFAT binding sites encoded
in the HIV LTR (Gaynor, 1992; Gomez-Roman et al., 2000;
Pessler and Cron, 2004). Although each of these sites
individually has been shown to have varied effects on viral
transcription, it is clear that in the aggregate, NFAT binding to
sites within the LTR increases viral replication (Pessler and
Cron, 2004). Considering that HIV gp120 activates NFAT and
facilitates binding to the NFAT recognition sequence encoded in
the IL2 promoter (Emmel et al., 1989), we asked whether
envelope-mediated signaling could promote binding of NFAT to
sequences encoded in the HIV LTR. To this end, we designed
several oligonucleotides that encode NFAT binding sites
contained within HIV- LTR (see Materials and methods), and
employed them as probes in EMSAs. Fresh PBMCs weretreated with an R5 gp120 for 4 h and nuclear lysates were
probed with a labeled oligonucleotide encoding one of the
NFAT recognition sequences encoded in the enhancer region of
the HIV LTR (probe #1). Among the NFAT recognition
sequences encoded in the HIV LTR this site is the best
characterized and most closely associated with enhanced viral
replication (Pessler and Cron, 2004). Relative to mock-treated
PBMCs we observed increased DNA-binding activity in the
nuclear lysate (Fig. 3A). This signal disappeared when an
unlabeled probe #1 (Fig. 3A), or an unlabeled probe encoding a
consensus NFAT recognition sequence was included (Fig. 3A).
To further demonstrate that this binding activity included NFAT
reactivity, we employed anti-NFAT1 and anti-NFAT2 mAbs to
induce a super-shift. Inclusion of these mAbs with the probe and
the gp120-treated lysate resulted in a reduction in the intensity
of the signal obtained in the absence of the NFAT mAbs, and the
appearance of a slower migrating band of diminished intensity
(Fig. 3B). A higher exposure of the slower migrating region of
the gel is included to better visualize the super-shifted band
(Fig. 3B insert). Supershifting with the anti-NFAT mAbs, along
with the disappearance of the signal in the presence of two
unlabeled NFAT probes indicate that NFATwas indeed binding
to the labeled probe upon gp120 stimulation.
We next asked whether other NFAT recognition sites encoded
in the HIV LTR could also bind gp120-activated NFAT. We
assayed two additional LTR-encoded NFAT recognition sites.
One NFAT recognition site comprised bp 206 to 166 (probe
#2). gp120 treatment of PBMCs was carried out as described
above. Again, we observed increased oligonucleotide binding
activity in the gp120-treated PBMCs relative to mock-treated
PBMCs (Fig. 4A). We carried out a super-shift analysis using
mAbs specific to NFAT1 and NFAT2. Inclusion of either mAb
produced a super-shift, indicating that gp120 treatment activates
both of these NFAT family members. In this experiment, we
observed a low basal level of activated NFAT2 in the mock-
treated sample, which is not a completely unexpected finding
insofar as this analysis was carried out on primary PBMCs from
an anonymous donor. To complete this analysis, we utilized an
oligonucleotide encoding a third NFAT recognition site encoded
in the HIV LTR, encompassing bp 275 to 240 (probe #3). In
addition, in order to establish that gp120 activates NFAT within
the CD4+ T-cell subset, we purified CD4+ T-cells by negative
selection and employed them in this EMSA. As with the two
previous oligonucleotide probes, gp120-treated lysates demon-
strated increased oligonucleotide reactivity, and the reactivity
super-shifted when anti-NFAT mAbs were included (Fig. 4B).
Thus, with respect to unstimulated CD4+ T-cells, gp120 activates
NFAT. Additionally, at least three different NFAT recognition
sites within the LTR are recognized by gp120-activated NFAT.
We previously reported that gp120 can induce viral
replication in resting CD4+ T-cells in the absence of cellular
activation (Kinter et al., 2003). Replication in resting CD4+ T-
cells may contribute to the maintenance of long-lived viral
reservoirs (Zhang et al., 1999). In this regard, we asked whether
gp120-mediated activation of NFAT occurs within the resting
CD4+ T-cell sub-population of PBMCs. CD4+/CD25-/CD69-/
HLADR-T-cells, which are widely regarded as the resting cell
Fig. 3. EMSA of gp120-treated PBMCs probed with an HIV LTR enhancer region encoded NFAT recognition sequence. Freshly isolated PBMCs were treated with
an R5 envelope (92UG037), and nuclear lysates were probed with an oligonucleotide probe encoding an NFAT recognition sequence located within the enhancer
region of the HIV LTR (residues 93 to 76, probe #1). Nuclear lysates were electrophoresed, transferred to nylon membrane and incubated with a streptavidin-
chemiluminescent conjugate (A, lanes 1 and 4). Replicate lysates were incubated with the same probe in the presence of unlabeled LTR enhancer probe (A, lanes 2
and 5) or a unlabeled NFAT consensus oligonucleotide probe (A, lanes 3 and 6). EMSA analysis of nuclear lysates from gp120-treated PBMCs probed with the
labeled LTR enhancer oligonucleotide (probe #1), in the presence (B, lane 2) or absence (B, lane 1) of two anti NFAT mAbs. A longer exposure of the slower
migrating section of the panel B gel is included (B, insert).
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important HIV reservoir, were isolated from fresh unstimulated
PBMCs by negative selection (Fig 5A), and stimulated for 4
h with an R5 gp120. An EMSA utilizing the IL2 NFAT
recognition sequence as a probe was carried out on nuclear
extracts (Fig. 5B). Relative to mock-treated cells, we observed a
clear increase in oligonucleotide reactivity. When lysates were
probed with the nonbinding IL2 NFAT probe mentioned above,
no signal was observed (Fig. 5B). The inclusion of an anti-
NFAT mAb resulted in a super-shifted band further demon-
strating NFAT identity. Control binding activity was assessed
with an oct-1 probe, which revealed similar signals in mock-
treated and gp120-treated lysates (Fig. 5B insert). The same
lysates were also probed with the HIV LTR sequence (probe
#2), that was shown above (Fig. 4) to bind NFAT in gp120-
treated whole PBMCs. A clear signal was observed only after
gp120 treatment (Fig. 5C). This signal disappeared when an
unlabeled probe was included in the reaction. Thus, as with
whole PBMCs, a gp120-mediated stimulus activates NFAT in
purified resting CD4+ T-cells, and promotes its binding to
sequences encoded within the HIV LTR.
Discussion
HIV gp120 induces an array of signaling events in CD4+ T
cells. Ligation through CD4 was first shown to promote the
phosphorylation of Lck (Goldman et al., 1994; Juszczak et al.,1991). Soon after CCR5 and CXCR4 were identified as
coreceptors for HIV, we and others demonstrated that gp120-
mediated signaling through CCR5 induces increased intracellu-
lar concentrations of free Ca2+ (Arthos et al., 2000; Weissman et
al., 1997), as well as the activation of FAK, ZAP70 and PYK2
(Cicala et al., 1999; Davis et al., 1997). Recently it has been
shown that the ligation of CD4 and coreceptor by gp120 induces
a rearrangement of the actin cytoskeleton (Jolly et al., 2004). The
role of these signaling events in the replication cycle of HIV and
in the pathogenesis of HIV disease is beginning to become clear.
A number of early studies focused on the potential role of gp120
in immune dysfunction by the induction of apoptosis in activated
CD4+ T-cells (Ameisen and Capron, 1991; Banda et al., 1992).
More recent studies have focused on the potential of these
signals to facilitate viral replication (Stantchev and Broder,
2001). We and others have reported that CC-chemokines, as a
consequence of their biological activity, can actually enhance
HIV replication in CD4+ T-cells (Dolei et al., 1998; Kinter et al.,
1998) and macrophages (Kelly et al., 1998). Because of the
obvious commonalities between gp120 signaling through CCR5
and CC-chemokine signaling through CCR5 we addressed the
possibility that gp120 itself could promote viral replication in
resting CD4+ T-cells, and found that in fact it does (Kinter et al.,
2003). To better understand the mechanisms whereby this
occurs, we evaluated the response of freshly isolated PBMCs
to gp120 treatment using high-density oligonucleotide micro-
arrays, and found that the transcriptional program induced by
Fig. 4. EMSA of gp120-treated PBMCs and purified CD4+ T-cells probed with
an LTR encoded oligonucleotide, and supershifted with NFAT1 and NFAT2
mAbs. Freshly isolated PBMCs were treated with an R5 gp120 (JR-FL) and
nuclear lysates were probed with a biotinylated oligonucleotide encoding an
NFAT recognition site encoded in the HIV LTR (nucleotides 206 to 166,
probe #2) (A). Lysates were derived from mock-treated PBMCs (A, lane 1) and
R5 gp120-treated PBMCs (A, lane 4). Nuclear lysates were also probed in the
presence of an NFAT1 mAb (A, lanes 2 and 5) and an NFAT2 mAb (A, lanes 3
and 6). R5 gp120 (92US715)-treated lysates derived from purified CD4+ T-
cells were also probed with an oligonucleotide encoding the HIV LTR NFAT
recognition site located at position 275 to 240 (probe #3) (B). Nuclear
lysates derived from mock-treated (panel B lanes 1) or R5 gp120-treated CD4+
T-cells (B, lanes 3) are shown. An excess of unlabeled oligonucleotide probe
(B, lanes 2 and 4), and a supershift with anti NFAT1 and anti NFAT2 mAbs (B,
lane 5) were included as specificity controls.
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products have been shown to be conducive to viral replication
(Cicala et al., 2002). NFAT was among those genes. Because of
its capacity to directly bind to the HIV LTR and promote viral
replication (Kinoshita et al., 1997), we evaluated NFAT
expression by Western blot and found that gp120 treatment
increased NFAT protein expression (Cicala et al., 2002).
In the present study, we have extended our analysis of the
relationship between gp120 signaling and NFAT. We employed
both R5 and X4 recombinant gp120s, at concentrations of 4 Ag/
107 cells. This concentration is near-saturating and should reflect
local concentrations of gp120 at sites of viral replication. We
have demonstrated that gp120 treatment of unstimulated PBMCs
induces the activation and nuclear translocation of NFAT. NFAT
activation was mediated by three genetically diverse R5 gp120s
and an X4 gp120 suggesting it is a property common to HIV
envelopes. However we cannot conclude from the data presentedin this report that all R5 and/or X4 envelopes are equally capable
of activating NFAT. We can speculate however that both the
binding properties (kinetics) of envelope–receptor interactions,
as well as the colocalization of CD4 and coreceptors on the cell
membrane can ultimately influence the efficiency with which a
particular envelope activates NFAT.
Additionally, we found that gp120 activates NFAT within
the population of resting CD4+ T-cells, which are an important
target for HIV infection. HIV replicates most efficiently in
highly activated CD4+ T-cells, however, low level replication
does take place in resting cells (Haase, 1999; Zhang et al.,
1999), and although infection and propagation of HIV in this T-
cell subset represents a small fraction of productively infected
cells, it plays a critically important role in the transmission of
HIV(Haase, 1999; Zhang et al., 1999). Moreover, unlike
infected proliferating cells, which are short lived, infected
resting cells persist, even in the face of antiretroviral therapy
(ART), and therefore represent an obstacle to the eradication of
HIV from infected individuals (Haase, 1999; Zhang et al.,
1999). Thus, in light of previous observations linking NFAT
activity with increased viral replication in resting CD4+ T-cells
(Cron et al., 2000; Kinoshita et al., 1998; Williams et al.,
2004), activation of NFAT by gp120 represents one potential
mechanism whereby HIV can create conditions within a resting
cell that favor productive infection. In this regard, gp120 is not
unique, the Nef protein of HIV has also been associated with
increased NFAT activation (Fortin et al., 2004; Manninen et al.,
2000; Wang et al., 2000). That HIV has evolved independent
mechanisms that increase NFAT activity may reflect the
importance of NFAT to the successful propagation of HIV.
With respect to HIV reservoirs, the resting CD4+ T-cell
population is defined phenotypically as that population
lacking cell surface activation markers (Chun et al., 1997;
Finzi et al., 1997), and is likely to consist of multiple
subpopulations in which various signal-transduction path-
ways, including those linked to the TCR, are differentially
activated (Wang et al., 2003). Because viral replication is
tightly linked to pathways associated with TCR activation, the
threshold of activation required for successful viral replication
and the contribution of activated NFAT to that replication will
vary (Oswald-Richter et al., 2004). A more precise definition
of these subpopulations, including the molecular events that
render them differentially susceptible to productive infection
and their potential to contribute to the resting T-cell reservoir
requires further study.
The HIV LTR encodes multiple NFAT recognition sites, and
some of these sites overlap with other transcription factor
binding sites including NFnB (Jones and Peterlin, 1994;
Pessler and Cron, 2004). As a consequence, the specific
influence of any given NFAT recognition site on viral
transcription can be complex. However, taken as a whole,
NFAT activation and recognition of sites within the HIV LTR is
associated with increased viral transcription (Pessler and Cron,
2004). To address the complexity of NFAT recognition of
multiple sites encoded in the HIV LTR, we evaluated NFAT
recognition of three different LTR -encoded NFAT recognition
sites. One of the sites is located within that region of the LTR
Fig. 5. EMSA of purified resting CD4+ lymphocytes. Resting CD4+ lymphocytes were purified from freshly isolated PBMCs and assayed for the cell surface
markers CD69, CD25 and HLA DR by flow cytometric analysis (A). A labeled oligonucleotide probe encoding the NFAT recognition site located in the IL2
promoter was employed in an EMSA of nuclear lysates obtained from resting CD4+ T lymphocytes. Cells were treated with either a mock protein preparation (B,
lanes 1) or an R5 gp120 (92US715) (B, lanes 4). Anti-NFAT-1 and -2 mAbs were used as a super-shift control (B, lanes 2 and 5). Nuclear lysates displayed in panel
B, lanes 1 and 4 were also probed with a control oct-1 oligonucleotide (panel a insert). The NFAT recognition sequence encoded in the HIV LTR (residues 206 to
166, probe #2) was also employed in an EMSA (C). Cells were treated with an R5 gp120 (92UG037) in the absence (C, lane 4) or presence of an excess of cold
unlabeled probe (C, lane 5). Nuclear extracts derived from cells treated with a mock protein preparation were also probed with the labeled LTR oligonucleotide in the
absence (panel C, lane 1) or presence (C, lane 2) of an excess of unlabeled probe. Labeled probe in the absence of cell lysate is included for reference (C, lane 3).
C. Cicala et al. / Virology 345 (2006) 105–114 111defined as the enhancer region, while two additional sites fall
upstream of the enhancer region (Gaynor, 1992; Pessler and
Cron, 2004). Probes representing each of these three sites
bound increased amounts of NFAT after gp120-treatment,
indicating that in unstimulated cells treated with gp120, all
three sequences are recognized. It should be noted that NFAT
may interact with other transcription factors that recognize sites
within the LTR. In fact, gp120-activated NFAT may displace
other transcription factors including NFnB p50 from the
enhancer region of LTR as has been reported (Macian and
Rao, 1999). Further study will be required to fully understand
the role of each of the NFAT recognition sites in transcriptional
regulation under varying states of activation, and within
different subsets of CD4+ T cells.gp120 is a unique signal transducing molecule in that it
delivers signals in a near simultaneous manner through two
receptors, CD4 and either CCR5 or CXCR4. Although
stimulating cells with an anti-CD4 mAb, MIP-1h or SDF-1
alone failed to activate NFAT, combinations of an anti-CD4
mAb and either MIP-1h or SDF-1 resulted in robust NFAT
activation. Because we were evaluating this response in whole
PBMCs and there are CD4/CCR5+ and CD4/CXCR4+
cells, it is possible that the increased NFAT activation that we
observed with dual stimuli could be explained by increasing
numbers of responding cells. However, NFAT activation
resulting from either stimulus alone yielded little if any NFAT
activation, thus the effect appears to be more than additive, and
suggests that within the population of CD4+ /CCR5+ or CD4+/
C. Cicala et al. / Virology 345 (2006) 105–114112CXCR4+ cells, the combined stimulus results in a more
efficient and synergistic activation of NFAT. In support of this
conclusion, coreceptor inhibitors completely blocked gp120-
mediated NFAT activation, demonstrating that gp120 must
engage either CCR5 or CXCR4 in order to activate NFAT. CD4
signal transduction is mediated through the src-related protein
tyrosine kinase p56lck (Juszczak et al., 1991), which is
physically associated with the cytoplasmic tail of CD4 (Rudd
et al., 1988; Veillette et al., 1988). Ligation of CD4 alone does
not induce calcium flux (Deans et al., 1992); therefore, it is not
unexpected that CD4 ligation alone fails to activate NFAT in
unstimulated PBMCs. Both CCR5 and CXCR4 are linked to
G-protein coupled receptors (GPCRs) and stimulation by their
ligands, MIP-1h and SDF-1, respectively, does induce in-
creased concentrations of free intracellular Ca2+ (Locati and
Murphy, 1999). Therefore, one might expect to observe
activation of NFAT in response to treatment with SDF-1 or
MIP-1h; however, under the conditions that we employed,
little if any NFAT activation was observed. The capacity of the
dual stimuli of an anti-CD4 mAb together with either SDF-1 or
MIP1-h to activate NFAT could reflect cooperative effects
between the two signal transducing pathways. Alternatively,
stimulation through the CD4 receptor may lead to rearrange-
ments of receptors on the plasma membrane and/or changes in
the cytoskeleton that facilitate chemokine receptor-mediated
Ca2+ mobilization. Jolly and colleagues have demonstrated that
X4 gp120 ligation to CD4+ cells recruits CXCR4 and CD4 into
polarized clusters and induces dramatic changes in the
architecture of the cytoskeleton. Changes associated with these
responses may underlie the synergistic response of cells to
stimulation through CD4 and CCR5 or CXCR4 with respect to
NFAT activation. How these two processes produce a
synergistic response requires further study.
In summary, we have demonstrated that both R5 and X4
gp120s induce the activation of NFAT in unstimulated primary
PBMCs. Using CD4-, CCR5- and CXCR4-specific ligands, we
determined that this activity requires dual stimulation through
CD4 and one of the coreceptors. We further demonstrated that
gp120 induces NFAT in resting CD4+ T-cells, which are an
important reservoir for HIV in chronically infected individuals.
The capacity of gp120 to activate NFAT in this subset of cells
may contribute to gp120-mediated induction of viral replica-
tion in these cells. In this regard, understanding the mechan-
isms by which gp120-mediated signal transduction promotes
viral replication will further our ability to identify strategies
that may eventually lead to more effective anti-viral therapies.
Materials and methods
Cells and reagents
Human peripheral mononuclear blood cells (PBMCs) and
purified CD4+ T-cells were obtained from healthy volunteers
by Ficoll-hypaque isolation. Purified CD4+ T-cells and resting
CD4+ T-cells were obtained by negative selection using
antibody-conjugated magnetic beads (StemCell Technologies,
Vancouver, BC) as previously described (Finzi et al., 1997).Resting cells were evaluated with cell surface activation
markers, CD69, CD25 and HLA DR by flow-cytometric
analysis with a Becton Dickinson Facscan (Franklin Lakes,
NJ). Cells were incubated in RPMI 1640 medium, containing
5% fetal bovine serum (FBS), and 2% penicillin/streptomycin/
glutamine (PSG). gp120 was expressed and purified as
previously described (Mossman et al., 1996) . Briefly, Chinese
hamster ovary (CHO) cell lines expressing recombinant gp120s
derived from HIV molecular clones were cultured in hollow-
fiber cartridges (Fibercell System, Frederick, MD). Protein was
purified in three steps, employing metal-chelating, lectin, and
size-exclusion chromatography. Protein concentrations were
determined by absorbance at wavelength 280 nanometers.
Protein was visualized by silver-stain and determined to be
greater than 97% pure and endotoxin-free (LAL assay;
BioWittaker, Walkerville, MD). A mock protein prepared in
an identical manner was derived from untransfected CHO cells
and used as a mock.
gp120 treatment of PBMCs
Freshly isolated PBMCs (1  108 per treatment) were
cultured in RPMI 1640 medium supplemented with 5% FBS
and 2% PSG. gp120 was incubated with PBMCs at a
concentration of 4 Ag/ml for a total of 4 h at 37 -C. Parallel
treatments were treated with a mock protein preparation and
served as a negative control. For CD4 crosslinking of cells, an
anti CD4 mouse mAb was preincubated with beads bearing a
purified goat anti-mouse antibody (Dynal Biotech ASA, Oslo
Norway) and then added to cells for a total of 4 h at 37 -C.
TAK779 and AMD3100, CCR5 and CXCR4 coreceptor
inhibitors respectively were obtained from the AIDS Reagent
Repository and reconstituted as recommended by the manu-
facturers, and employed as previously described (Baba et al.,
1999; Schols et al., 1997).
Preparation of nuclear extracts
To obtain nuclear extracts lysates, PBMCs were washed with
ice-cold 1 PBS and lysed using NE-PER Nuclear Extraction
Reagents (Pierce, Rockford, IL). Protein concentrations of
cellular extracts were determined by the bicinchoninic assay
with a commercial protein reagent kit (Pierce, Rockford, IL).
Electrophoretic mobility shift assays (EMSA)
EMSAs were performed utilizing biotin end labeled DNA.
Oligonucleotides were end labeled separately using Biotin
3VEnd DNA Labeling Kit (Pierce, Rockford, IL). Briefly, 5
pmol of individual oligonucleotides were labeled utilizing TdT
to incorporate 1–3 biotinylated ribonucleotides onto the 3V end
of DNA strands. Oligonucleotides were then annealed prior to
use in subsequent EMSAs. The LightShift Chemiluminescent
EMSA kit (Pierce, Rockford, IL) was used for EMSAs. Briefly,
3 Ag of nuclear extracts were incubated in binding buffer
containing 100 mM Tris, 500 nM KCL, 10 mM DTT, pH 7.5, 2
Ag of Poly dI dC along with 20 fentomoles of biotin labeled
C. Cicala et al. / Virology 345 (2006) 105–114 113double stranded oligonucleotides for a total volume of 20 Al.
Reaction mixtures were incubated for 30 min at room
temperature. DNA–protein complexes were resolved on 6%
DNA retardation gels (Novex, Carlsbad, CA). The gels were
subsequently transferred to nylon membranes and detected
according to manufacturer’s instructions. Cold competition
assays were carried out by adding a 100-fold molar excess of
unlabeled oligonucleotide probe prior to the addition of labeled
probe. A consensus sequence for NFATc was also used to
determine corresponding bands for NFATc binding (Santa Cruz
Biotechnology, Santa Cruz, CA). Supershift assays were
performed by the incubation of NFAT antibodies overnight at
4 -C after the reaction was incubated with labeled probe. The
following oligonucleotides were used as probes for the EMSA:
NFAT motif in the IL2 promoter: 5VGGAGGAAAAAQ
CTGTTTCATACAGAAGGCGT-3V
Nonbinding derivative of the NFAT motif in the IL2
promoter: 5V CGTCCTAAAACTGTTTCATACAGAAQ
GGCGT 3V (Park et al., 1996).
HIV LTR NFAT binding site oligonucleotide probes were
based upon sites identified by Gomez-Roman and colleagues
(Gomez-Roman et al., 2000). Specific sequences were derived
from the HIV subgroup B consensus sequence listed in the NIH
HIV sequence data base (www.hiv.lanl.gov/content/hiv-db/).
The HIV LTR promoter (B subgroup consensus sequence):
probe #1: bp 93 to 76; 5V-CTGGGGAC TTTCCAGGG-
3V (Cron et al., 2000)
probe #2: bp 206 to 166; 5V-CAGAGAAGGTAGAA-
GAGG CCAATGAAGGAGAGAACAACAG-3V
probe #3: bp 275 to 240; 5V AGGACCCGGAGAAA-
GAAGTGTT AGTGTGGAAG 3V.
oct-1 housekeeping gene control probe: 5-TGTCGAATG-
CAAATCACTAG-3 (Badran et al., 2002).
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